# Haemophilus influenzae type b vaccine (Hib) CDC recommendations- tabular CDSS rules (optimal)

Updated on 2024-04-23

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Vaccine** | **#** | **Age1** | **Age2** | **SpecialCondition** | **Immunization record** | | | **MedIndication1** | **MedIndication2** | **MedIndication3** | **Todo1** | **Todo2** | **Todo3** | **Todo4** | **Todo5** | **Note-display** | **Note** |
|  |  |  |  |  | **Y/N** | **Dose** | **Adm date** |  |  |  |  |  |  |  |  |  |  |
| **Haemophilus influenzae type b vaccine : Hib(PRP-T), Hib(PRP-OMP)** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | Minimal age: 6 wks |
| **Regular and catch-up schedule** | | | | | | | | | | | | | | | | | |
| ActHIB, Hiberix, Pentacel, Vaxelis | 1 | = 2 mon |  |  | N |  |  |  |  |  | Admin 1st dose | Schedule 2nd dose at age of 4 mon | Schedule 3rd dose at age of 6 mon | Schedule booster dose at the age between 12-15 mon |  |  | Booster can be ActHIB, Hiberix or Pentacel only; Vexelis is not recommended to be a booster dose |
|  | 2 | >= 4 mon | <= 12 mon | At least one dose was PRP-T (ActHib, Pentacel, Hiberix), Vaxelis or unknown | Y | 1 | Admin when age < 7 mon |  |  |  | Admin 2nd dose >= 4 wks from 1st dose | Schedule 3rd dose >= 4 wks from 2nd dose |  |  |  |  |  |
|  | 3 | >= 4 mon | <= 6 yrs |  | Y | 1 | Admin at age 7-11 mon |  |  |  | Admin 2nd dose >= 4 wks from 1st dose | Admin 3rd dose at age of 12-15 mon AND >= 8 wks from 2nd dose |  |  |  |  |  |
|  | 4 | >= 4 mon | <= 6 yrs |  | Y | 1 | Admin at age < 12 mon |  |  |  | Admin 2nd dose >= 4 wks from 1st dose |  |  |  |  |  |  |
|  | 5 | >= 4 mon | <= 6 yrs |  | Y | 1 | Admin at age 12-14 mon |  |  |  | Admin 2nd dose >= 8 wks from 1st dose |  |  |  |  |  |  |
|  | 6 | >= 4 mon | <= 6 yrs |  | Y | 1 | Admin at age >= 15 mon |  |  |  | No further dose is needed |  |  |  |  |  |  |
|  | 7 | >= 4 mon | <= 12 mon |  | Y | 2 | Admin 1st dose when at age 7-11 mon |  |  |  | Admin 3rd dose >= 8 wks from 2nd dose AND at age 12-59 mon |  |  |  |  |  |  |
|  | 8 | >= 12 mon | <= 59 Mon |  | Y | 2 | Admin 1st dose at age < 12 mon AND dose 2 at age < 15 mon |  |  |  | Admin 3rd dose >= 8 wks of 2nd dose AND at age 12-59 mon |  |  |  |  |  |  |
|  | 9 | >= 4 mon | <= 59 mon |  | Y | 3 | Admin all before age of 12 mon |  |  |  | Admin 4th dose >= 8 wks from 3rd dose |  |  |  |  |  |  |
|  | 10 | >= 15 mon | <=59 mon |  | N |  |  |  |  |  | Admin 1st dose |  |  |  |  |  |  |
|  | 11 | >=60 mon |  | Not considered high risk | N |  |  |  |  |  | Do not admin |  |  |  |  |  |  |
| PedvaxHIB | 12 | = 2 mon |  |  | N |  |  |  |  |  | Admin 1st dose | Schedule 2nd dose at age of 4 mon | Schedule a 3rd dose as a booster at age of 12-15 mon |  |  |  |  |
| PedvaxHIB | 13 | >= 4 mon | <= 6 yrs |  | Y | 2 | Admin before age of < 12 mon |  |  |  | Admin 3rd dose at age of 12 – 59 mon AND >= 8 wks from 2nd dose |  |  |  |  |  |  |
| **Special situations** | | | | | | | | | | | | | | | | | |
| Chemotherapy or radiation treatment (doses administered within 14 days of starting therapy or during therapy should be repeated at least 3 months after therapy completion) | | | | | | | | | | | | | | | | | |
|  | 14 | >= 12 mon | <= 59 mon |  | N |  |  |  |  |  | Admin 1st dose | Schedule 2nd dose >= 8 wks from 1st dose |  |  |  |  |  |
|  | 15 | >= 12 mon | <= 59 mon |  | Y | 1 | Admin before age <12 mon |  |  |  | Admin a dose >= 8 wks from 1st dose | Schedule another dose >= 8 wks from 2nd dose |  |  |  |  |  |
|  | 16 | >= 12 mon | <= 59 mon |  | Y | 2 | Admin both before age <12 mon |  |  |  | Admin 3rd dose >= 8 wks from 2nd dose |  |  |  |  |  |  |
|  | 17 | >= 12 mon | <= 59 mon |  | Y | 3 | Admin all before age 12 mon |  |  |  | Admin one more dose >= 8 wks from 3rd dose |  |  |  |  |  |  |
| Hematopoietic stem cell transplant (HSCT) | | | | | | | | | | | | | | | | | |
|  | 18 |  |  | After successful transplant, regardless of Hib vaccination history |  |  |  |  |  |  | Admin 1st dose after transplant 6 – 12 mon | Schedule 2nd dose >= 4 wks from 1st dose | Schedule 3rd dose >= 4 wks from 2nd dose |  |  |  |  |
| Anatomic or functional asplenia (including sickle cell disease) | | | | | | | | | | | | | | | | | |
|  | 19 | >= 12 mon | <= 59 mon |  | N |  |  |  |  |  | Admin 1st dose | Schedule 2nd dose >= 8 wks from 1st dose |  |  |  |  |  |
|  | 20 | >= 12 mon | <= 59 mon |  | Y | 1 | Admin before age <12 mon |  |  |  | Admin a dose >= 8 wks from 1st dose | Schedule another dose >= 8 wks from 2nd dose |  |  |  |  |  |
|  | 21 | >= 12 mon | <= 59 mon |  | Y | 2 | Admin before age <12 mon |  |  |  | Admin one dose >= 8 wks from 2nd dose |  |  |  |  |  |  |
|  | 22 | >= 12 mon | <= 59 mon |  | Y | 3 | Admin before age <12 mon |  |  |  | Admin one dose >= 8 wks from 3rd dose |  |  |  |  |  |  |
|  | 23 | >= 5 yr |  |  | N |  |  |  |  |  | Admin 1 dose |  |  |  |  |  |  |
| Elective splenectomy | | | | | | | | | | | | | | | | | |
|  | 24 | >= 15 mon |  | No dose or less than routine series through 14 mon | N |  |  |  |  |  | Admin 1 dose >= 14 days before procedure |  |  |  |  |  |  |
| HIV infection | | | | | | | | | | | | | | | | | |
|  | 25 | >= 12 mon | <= 59 mon |  | N |  |  |  |  |  | Admin 1st dose | Schedule 2nd dose >= 8wks from 1st dose |  |  |  |  |  |
|  | 26 | >= 12 mon | <= 59 mon |  | Y | 1 | Admin before age 12 mon |  |  |  | Admin a dose >= 8 wks from 1st dose | Schedule another dose >= 8 wks from 2nd dose |  |  |  |  |  |
|  | 27 | >= 12 mon | <= 59 mon |  | Y | 2 | Admin before age 12 mon |  |  |  | Admin one dose >= 8 wks from 2nd dose |  |  |  |  |  |  |
|  | 28 | >= 12 mon | <= 59 mon |  | Y | 3 | Admin before age 12 mon |  |  |  | Admin one dose >= 8 wks from 3rd dose |  |  |  |  |  |  |
|  | 29 | >= 5 yrs | <= 18 yrs | No dose or less than routine series | N |  |  |  |  |  | Admin 1 dose >= 8 wks from the most recent dose |  |  |  |  |  |  |
| Immunoglobulin deficiency, early component complement deficiency | | | | | | | | | | | | | | | | | |
|  | 30 | >= 12 mon | <= 59 mon |  | N |  |  |  |  |  | Admin 1st dose | Schedule 2nd dose >= 8wks from 1st dose |  |  |  |  |  |
|  | 31 | >= 12 mon | <= 59 mon |  | Y | 1 | Admin before age 12 mon |  |  |  | Admin a dose >= 8 wks from 1st dose | Schedule another dose >= 8 wks from 2nd dose |  |  |  |  |  |
|  | 32 | >= 12 mon | <= 59 mon |  | Y | 2 | Admin before age 12 mon |  |  |  | Admin one dose >= 8 wks from 2nd dose |  |  |  |  |  |  |
|  | 33 | >= 12 mon | <= 59 mon |  | Y | 3 | Admin before age 12 mon |  |  |  | Admin one dose >= 8 wks from 3rd dose |  |  |  |  |  |  |
| **Contraindications and precautions** | | | | | | | | | | | | | | | | | |
|  | 34 |  |  |  |  |  |  | Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component |  |  | Do not admin |  |  |  |  |  | Contraindication |
|  | 35 |  |  |  |  |  |  | For Hiberix, ActHib, and PedvaxHIB only, history of severe allergic reaction to dry natural latex |  |  | Do not admin |  |  |  |  |  | Contraindication |
|  | 36 |  |  |  |  |  |  | Age < 6 weeks |  |  | Do not admin |  |  |  |  |  | Contraindication |
|  | 37 |  |  |  |  |  |  | Moderate or severe acute illness with or without fever |  |  | Only admin if benefits outweigh risks to an adverse reaction |  |  |  |  |  | Precaution |
| DTaP-IPV-Hib-HepB (Vaxelis) | | | | | | | | | | | | | | | | | |
|  | 38 | >= 6 wks | < 5 yrs |  | N |  |  |  |  |  | Admin 1st dose | Schedule 2nd dose >= 4 wks from 1st dose AND age >= 10 wks | Schedule 3rd dose >= 4 wks from 2nd dose AND age >= 24 wks |  |  |  | Do not admin at or after 5 yrs any dose |
|  | 39 |  |  |  | Y | 3 | 3rd dose before age 24 wks |  |  |  | Admin an additional dose of hepatitis B vaccine when age >= 24 wks |  |  |  |  |  |  |